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Mesenchymal stromal cells (MSC) have shown immunomodulatory and tissue repair poten-
tial including partial tolerance induction by pre-treatment of donor-speciﬁc cells in a rat heart
transplantation model. Very recently, we could show that autologous MSC attenuated
ischemia reperfusion injury in a highly mismatched donor–recipient rat kidney transplant
model. Therefore, we investigated donor-speciﬁc MSC pre-treatment in this rat kidney
transplantation model to study whether graft function could be improved, or if tolerance
could be induced. Donor- and recipient-type MSC or phosphate buffered saline (PBS) as
a control was injected i.v. 4 days before kidney transplantation. Mycophenolate mofetil
immunosuppression (20 mg/kg body weight) was applied for 7 days. Kidney grafts and
spleens were harvested between days 8 and 10 and analyzed by quantitative RT-PCR and
immunohistology. In addition, creatinine levels in the blood were measured and serum
was screened for the presence of donor-speciﬁc antibodies. Surprisingly, application of
both donor- and recipient-speciﬁc MSC resulted in enhanced humoral immune responses
veriﬁed by intragraft B cell inﬁltration and complement factor C4d deposits. Moreover,
signs of inﬂammation and rejection were generally enhanced in both MSC-treated groups
relative to PBS control group. Additionally, pre-treatment with donor-speciﬁc MSC sig-
niﬁcantly enhanced the level of donor-speciﬁc antibody formation when compared with
PBS- or recipient MSC-treated groups. Pre-treatment with both MSC types resulted in
a higher degree of kidney cortex tissue damage and elevated creatinine levels at the
time point of rejection. Thus, MSC pre-sensitization in this model impairs the allograft
outcome. Our data from this pre-clinical kidney transplantation model indicate that pre-
operative MSC administration may not be optimal in kidney transplantation and caution
must be exerted before moving forward with clinical studies in order to avoid adverse
effects.
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INTRODUCTION
Kidney transplantation outcomes have been greatly improved over
the last few years by better immunosuppression regimens and
post-operative care. However, due to organ shortages, often the
donor kidneys available are sub-optimal or so-called “marginal
organs,” which has been shown to lead to greater problems with
immunogenicity and worse long-term function (Audard et al.,
2008; Stallone et al., 2010). Several attempts have been devel-
oped to help reduce damage to the graft that may occur before
the transplant (van der Woude et al., 2004; Kotsch et al., 2007;
Caumartin et al., 2011), however, many treatment regimes are
not suited for use with human patients. More recent strategies
have focused on using cell therapies from different sources to
help stimulate the regeneration of cells inside the transplanted
organ (Bussolati and Camussi, 2006; Morigi et al., 2006; Choi
et al., 2010; Harari-Steinberg et al., 2011; Little, 2011; Bussolati
et al., 2012). In particular, the reduction of ischemia reperfu-
sion injury by use of protective cells or their products has been
an area of intense research in the hopes of increasing long-term
survival and kidney function (Donizetti-Oliveira et al., 2012;
Furuichi et al., 2012).
Recently, the potential therapeutic use of mesenchymal stro-
mal cells (MSC) has been investigated in many model systems.
Based on the discovery of various properties of MSC to help in
the repair of damaged tissues and to promote immunomodu-
latory functions, a great deal of promise has been invested in
this cell type (Yagi et al., 2010; Hoogduijn et al., 2011; Shi et al.,
2011; Singer and Caplan, 2011; Tögel and Westenfelder, 2011). In
animal experiment models of graft versus host disease (GvHD),
skin transplantation, and in particular heart transplantation,MSC
have been described as promoting protective effects (Bartholomew
et al., 2002; Le Blanc et al., 2004; Maitra et al., 2004; Zhou et al.,
2006; Eggenhofer et al., 2011). In a rat heart transplantationmodel,
bone marrow derived donor- and recipient-type MSC adminis-
tered concurrent to the time point of grafting were not able to
prolong heart allograft survival or even led to accelerated rejec-
tion with concurrent low-dose Cyclosporin A treatment (Inoue
et al., 2006). In contrast, pre-treatment with allogeneic MSC
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under mycophenolate mofetil (MMF) immunosuppression in the
same rat transplantation model induced partial tolerance toward
the transplanted organ, whereas syngeneic cells were less effective
(Popp et al., 2009).
Beneﬁcial effects of MSC on renal function were mostly
described in models of acute kidney injury induced by temporary
vessel ligation. In this experimental setup, MSC administration
has been clearly shown to reduce kidney damage as measured
by reduced serum creatinine and urea levels (Tögel et al., 2005;
Semedo et al., 2007; Cao et al., 2010; De Martino et al., 2010;
Morigi et al., 2010). In addition, we could very recently show in a
rat renal transplantationmodel that repeated recipientMSC appli-
cation was able to ameliorate damage following prolonged cold
ischemia at early time points by reducing the expression of pro-
inﬂammatory cytokines and inﬁltration by antigen-presenting
cells (APC) in the grafted kidney (Hara et al., 2011). However,
in this acute pre-clinical model the allograft survival was not
improved. As these results fell short of our expectations, we have
focused on reports in the heartmodel that indicated that allogeneic
MSC under MMF immunosuppression might be more effective
(Popp et al., 2009).
Here, we describe that the protocol which was successful in
a heart transplant model cannot simply be transferred to kidney
transplantation. Allogeneic MSC do not induce tolerance to the
graft, but they actually worsen the outcome. We have found that
the deleterious effects of both donor- and recipient-type MSC are
related to the induction of humoral immune responses, associ-
ated inﬁltration of B cells, and increased C4d deposits attributed
to complement activation in the allograft. We also found indica-
tions that the allogeneic MSC could lead to a pre-sensitization of
the recipient to donor antigens as shown by the enhancement of
donor-speciﬁc antibodies that could accelerate the pace of organ
rejection instead of hindering it.
MATERIALS AND METHODS
ANIMALS
Adult male Dark Agouti (DA; MHC haplotype RT1av; Harlan-
Winkelmann, Borchen, Germany) and Lewis (LEW; MHC haplo-
typeRT1l) inbred rats (CharlesRiver, Sulzfeld,Germany)weighing
approximately 250–300 g were maintained in the animal facility of
the Charité Virchow clinic. All animal procedures were performed
in accordance with the approval of the local authority for animal
research procedures, the Landesamt für Gesundheit und Soziales,
Berlin, Germany, and conformed to all relevant regulatory stan-
dards for animal research. The rats were anesthetized with inhaled
isoﬂurane.
MSC ISOLATION AND CULTURE
Mesenchymal stromal cells were harvested from bone marrow
of femurs and tibias from adult male LEW or DA rats by cen-
trifugation of the bone shaft as described elsewhere (Hara et al.,
2011). MSC at passages 3–5 and a content of <5% CD45+ cells
as conﬁrmed by ﬂow cytometry were used for all experiments
described. MSC displayed a typical phenotype pattern: CD90+,
CD73+, major histocompatibility complex (MHC) I+, intercellu-
lar adhesion molecule (ICAM)+, VCAM−, MHCII−, CD86−, and
weak CD80+ as described elsewhere (Hara et al., 2011; see also
Appendix Figure A1).
KIDNEY TRANSPLANTATION
Donor kidneyswere removed fromDA rats and then perfusedwith
and stored in University of Wisconsin (UW) perfusion solution
(Charité, Berlin, Germany) at 4◦C while the recipient animal was
prepared. The total cold ischemic time was 35 ± 5 min. Follow-
ing cross-clamping of the abdominal aorta and the inferior vena
cava, the left kidney of the LEW recipient rat was removed. The
DA kidney was transplanted orthotopically with an end-to-side
aortic patch and performing an end-to-end venous anastomosis
using 10-0Prolene® (Ethicon; Johnson& JohnsonMedicalGmbH,
Norderstedt, Germany) running sutures. The ureter was recon-
structed by using an end-to-end anastomosis, performed by four
discontinuous stitches with 10-0 Ethilon® (Ethicon). The total
warm ischemic time of the graft during the attachment of the new
kidney was approximately 15 min.
EXPERIMENTAL DESIGN
As outlined in Figure 1, 4 days prior to kidney transplanta-
tion, two million bone marrow-derived MSCs from DA or LEW
rats, or phosphate buffered saline (PBS) as control was injected
intravenously. The immunosuppressant mycophenolate mofetil
(MMF/Cell Cept; Roche, Basel, Switzerland) was injected i.p. at a
dosage of 20 mg/kg body weight as described in a study of MSC
in heart transplantation (Popp et al., 2009) under mild isoﬂurane
anesthesia daily for 7 days from the day of transplant (day 0).
Transplanted rats were monitored daily for signs of illness due to
rejection or side effects of the MMF treatment. The contralateral
(right side) kidney was removed at day 7 after transplant. Signs
of rejection appeared beginning at day 8 for all groups. Data were
collected from ﬁve to six individual animals in each treatment
group that were transplanted and treated independently with two
to three transplantations performed per week (n = 5–6). Please
note that the creatinine measurement is only shown for n = 4–6
animals per group as this data was not measured from one animal.
The rats were anesthetized with isoﬂurane and blood was col-
lected from the aorta using a catheter (VenﬂonTM Pro 22GA;
BD Biosciences, Heidelberg, Germany) into a serum collection
tube (Vacutainer® SST II, 8.5 ml; BD Biosciences) with an addi-
tional blood drop placed onto a CREA Reﬂotron strip to measure
creatinine levels using a Reﬂotron® Plus Clinical Chemistry anal-
yser (Roche Diagnostics, Mannheim, Germany). After perfusing
the transplanted kidney with cold saline, the grafted kidney and
recipient spleen were collected for further analysis by PCR or
immunohistochemistry.
QUANTITATIVE REAL-TIME RT-PCR
Harvested organs were carefully cut into smaller pieces, immedi-
ately snap frozen in liquid nitrogen and stored at −80◦C. Kidneys
and spleens were thawed and homogenized before total RNA
was extracted using the Nucleospin II RNA kit (Macherey-Nagel
GmbH & Co.KG, Düren, Germany) and quantiﬁed using the
Nanodrop 1000 device and v3.7.1 software (Peqlab, Erlangen, Ger-
many). A reverse transcription reaction was performed using 3 μg
total RNA in a total volume of 30 μl using the high capacity cDNA
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FIGURE 1 | Experimental flow chart of in vivo study design.
DA (DA, RT1av) kidneys were harvested, perfused with UW solution and
kept at 4◦C before being transplanted orthotopically into Lewis (LEW, RT1Al)
recipients. MMF treatment was given daily from day 0 to 7 at a dosage of
20 mg/kg body weight. Two million donor-type DA-MSC or recipient-type
LEW-MSC or PBS controls were intravenously injected 4 days before
transplantation with ﬁve to six animals in each group. Eight to ten
days after transplantation, rats were humanely euthanized and
tissues were harvested for further analysis by real-time PCR and
immunohistology.
reverse transcription kit (Applied Biosystems/Life Technologies
GmbH, Darmstadt, Germany) in an Eppendorf Mastercycler
personal thermal cycler (Eppendorf, Hamburg, Germany) using
the conditions 10 min at 25◦C, 2 h at 37◦C, and 5 s at 85◦C as rec-
ommended by the manufacturer. Quantitative real-time PCR was
performed using the Eppendorf realplex2 Mastercycler machine
with a total reaction volume of 20 μl in 0.2 ml MicroAmp®
Optical Tubes and strip lids (Applied Biosystems) for a total of
40 cycles. The PCRs for tumor necrosis factor α (TNFα), inter-
feron γ (IFNγ), interleukin-6 (IL-6), CD25, and MHC class II
were performed using TaqMan chemistry (TaqMan® Universal
PCR Mastermix; Applied Biosystems), and for chemokine ligand
(CCL) 21, IL-1β, and β-actin using SYBR® Green qPCR Mas-
terMix Plus dTTP for SYBR® Assay ROX (Eurogentec, Seraing,
Belgium). Primers and probes were synthesized by Metabion
(Martinsried, Germany) with sequences given in Table 1. For
ICAM-1, an assay on demand was used (Applied Biosystems).
The speciﬁcity of the desired gene products was determined by
melting-curve analysis. Expression of the housekeeping gene β-
actin was used to normalize expression of the target gene within
the test sample and the mean fold increase of the target gene in
the test samples compared to the values in the kidneys or spleens
of three naïve rats was calculated using the formula 2−CT
(Livak and Schmittgen, 2001).
IMMUNOHISTOCHEMISTRY FOR INTRAGRAFT CELLULAR INFILTRATION
Harvested organs were prepared for immunohistochemistry by
ﬁrst ﬁxing the tissues with 2% paraformaldehyde (PFA; Sigma-
Aldrich, Taufkirchen, Germany) for 2 h and were then transferred
to 30% ﬁlter-sterilized sucrose (Calbiochem/Merck, Darmstadt,
Germany) for 1 or 2 days before being embedded in Jung
Tissue Freezing Medium (Leica, Nussloch, Germany) and stored
at −80◦C. Sections of kidney or spleen tissues 5–8 μm thick
were prepared using a Leica CM3050S cryostat and mounted
onto Superfrost Plus slides (R. Langenbrinck, Emmendingen,
Germany). Slides were blocked with Dual Enzyme blocking
reagent (Dako Deutschland GmbH, Hamburg, Germany) for
10 min and washed, followed by 1 h with Tris buffered saline
(TBS)/Tween/1% Bovine serum albumin (BSA)/10% horse serum
before the addition of speciﬁc monoclonal mouse anti-rat anti-
bodies to a B cell marker (clone KiB1R; BMA Biomedicals,
Augst, Switzerland), MHC class II (MHCII/RT1B; clone OX-6;
BD Pharmingen, San Diego, USA), CD45 (clone OX-1; AbD-
Serotec, Düsseldorf, Germany), CD68 (clone ED1; AbDSerotec),
T cell receptor (TCR; clone R73; Biolegend, San Diego, USA) or
with IgG isotype-identical control antibody (clone MOPC; Biole-
gend) overnight at 4◦C. The primary antibody was thoroughly
washed before incubation with the Secondary Antibody (anti-
mouse IgG (H + L)-biotin, rat absorbed (Vector, Burlingame,
CA, USA) for 1 h at room temperature, followed by incuba-
tion with streptavidin/horseradish peroxidase (Streptavidin/HRP;
Dako Deutschland GmbH) and then visualized using substrate
(3-amino-9-ethylcarbazole; AEC)-solution (Dako Deutschland
GmbH). Samples were counterstained with Harris’s hematoxylin
to detect cell nuclei and embedded in Aquatex (Merck, Darm-
stadt, Germany). Images were obtained by light microscopy
using a Zeiss Axioskop 40 microscope (Carl Zeiss MicroImag-
ing GmbH, Göttingen, Germany) with three images captured
from each slide and then analyzed in a blinded approach by three
different independent investigators. Signal intensities were graded
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Table 1 | Primer and probe sequences used for real-time RT-PCR analysis.
Gene Forward primer Reverse primer Probe
TNFα 5′-tcg agt gac aag ccc gta gc-3′ 5′-ctc agc cac tcc agc tgc tc-3′ 5′-cgt cgt agc aaa cca cca agc aga-3′
IFNγ 5′-aac agt aaa gca aaa aag gat gca tt-3′ 5′-ttc att gac agc ttt gtg ctg g-3′ 5′-cgc caa gtt cga ggt gaa caa ccc-3′
IL-1β 5′-acc aaa aat gcc tcg tgc tgt ct-3′ 5′-tgt tgg ctt atg ttc tgt cca ttg-3′ 5′-acc cat gtg agc tga aag ctc tcc acc-3′
IL-6 5′-aac tcc atc tgc cct tca gga-3′ 5′-ggc agt ggc tgt caa caa cat-3′ 5′-ttt ctc tcc gca aga gac ttc cag cca-3′
CCL21 5′-cca tcc cag caa tcc tgt tc-3′ 5′-cct cag ggt ttg cgc ata-3′ –
MHC class II 5′-ggt tga gaa cag caa gcc agt c-3′ 5′-ggt gag gta agc cat ctt gtg g-3′ 5′-tga gac cag ctt cct ttc caa ccc tga-3′
CD25 5′-cac agt ctg tgt acc aggaga acc t-3′ 5′-cca cga agt ggt aga ttc tct tgg-3′ 5′-cag gtc act gca ggg agc ccc c-3′
β-actin 5′-gta caa cct cct tgc agc tcc t-3′ 5′-ttg tcg acg acg agc gc-3′ 5′-cgc cac cag ttc gcc atg gat-3′
as scores between 0 and 3 (0 = no staining, 1 = weak staining,
2 = moderate staining, 3 = strong staining). The scores obtained
were graphed and analyzed in GraphPad Prism v5. Additional
slides were stained for 4 min with Harris’s hematoxylin, washed
twice with water, counterstained for 2 min with Eosin (both
from Sigma-Aldrich, Taufkirchen, Germany), washed again and
embedded with Entellan® (Merck) to evaluate tissue integrity.
C4d STAINING
Immunoﬂuorescence techniques were used to evaluate comple-
ment staining using a polyclonal antibody to rat C4d (Hycult
Biotech, Uden, The Netherlands) which was incubated overnight
at 4◦C followed by an Alexa Fluor® 488 donkey anti-rabbit IgG
(H + L) antibody (Jackson ImmunoResearch Europe Ltd., Suf-
folk, UK) for 90 min and covered with a DAPI mounting medium
(Dianova, Hamburg, Germany). Images were obtained by ﬂuores-
cence microscopy using a Zeiss Axis Observer Z1 microscope. The
total area of positive C4d staining in square pixels was quantiﬁed
using the ColumbusTM Image Data Storage and Analysis System
v2.3.0 (Perkin Elmer, Waltham, USA).
DETECTION OF DONOR-SPECIFIC ANTIBODIES
Thymocytes were isolated from naïve male DA rats (200–250 g
body weight) and made into a single cell suspension in Dul-
becco’s PBS (PAA, Pasching, Austria) by homogenization through
a 40μm cell strainer (Falcon, Oxnard, USA), and frozen in 90%
fetal calf serum (FCS; Biochrom AG, Berlin, Germany), 10%
dimethylsulfoxide (DMSO; Sigma, Taufkirchen, Germany) until
use. The cells were thawed, washed twice in RPMI (PAA) with
2 mM L-glutamine (Life Technologies, Darmstadt, Germany)
100 units/ml penicillin and 100 μg/ml streptomycin (both from
Life Technologies), containing 10% FCS (Biochrom AG) and
incubated in a 37◦C humidiﬁed incubator with 5% CO2 for
2 h. Thymocytes were washed again in cold PBS containing 1%
FCS, strained through a 40μm cell sieve to remove clumps, and
counted using a Fuchs Rosenthal cell chamber before 0.5 mil-
lion cells were distributed into each 1.4 ml ﬂow cytometry tube
(Micronic, Lelystad, The Netherlands) and incubated with the
serum collected from the test rats (or a naïve LEW rat as con-
trol) diluted 1:10 with PBS and incubated for 45 min at 4◦C
with occasional vortexing. Cells were washed thoroughly before
incubation with Goat-anti-Rat-Fab2-FITC secondary antibodies
for anti-IgG or anti-IgM (STAR 69 and STAR 116F; both from
AbDSerotec, Düsseldorf, Germany) for 30 min at 4◦C, washed
again and ﬁxed with 1% PFA (Sigma) until FACS analysis. Flow
cytometry was performed using the BD FACS Canto II (BD Bio-
sciences, Heidelberg, Germany) and further analysis with FlowJo
8.8.5 Software (TreeStar Inc., Ashland, USA) was used to deter-
mine the geometric mean ﬂuorescence intensity (MFI) of FITC
labeling. Background staining was calculated for a naïve Lew
serum sample and subtracted from the test rat values.
STATISTICAL ANALYSIS
All data are presented as means ± SEM. Data were analyzed for
statistical signiﬁcance by one-way analysis of variance (ANOVA)
with the Bonferroni post-test for differences between groups using
GraphPad Prism v5 software. P values of <0.05 were considered
signiﬁcant.
RESULTS
NEGATIVE IMPACT OF MSC ON KIDNEY GRAFT FUNCTION
When serum creatinine levels were measured after removing the
contralateral kidney, we found highest values in the DA-MSC-
treated group which were signiﬁcantly different to the PBS control
group. Moreover, the creatinine values of the LEW-MSC-treated
group were also signiﬁcantly elevated, indicating reduced kid-
ney function after injection of either type of MSC (Figure 2A).
Hematoxylin-Eosin (HE) staining of cryosections corroborated
these kidney function ﬁndings by indicating extreme destruction
of the architecture of glomeruli and tubuli within the DA-MSC
and LEW-MSC groups (Figures 2B,C) in comparison to the
PBS-treated animals (Figure 2D).
ENHANCED INFLAMMATION BY MSC IN RENAL ALLOGRAFTS
Kidney grafts were analyzed by quantitative PCR for their expres-
sion levels of inﬂammatory cytokines, chemokines, and cellular
markers compared to naïve rats as shown in Figure 3. Although
we could not ﬁnd any signiﬁcant differences between the expres-
sion level for all tested markers due to individual variations, it was
obvious that PBS-injected animals in general showed lower values,
especially for TNFα (Figure 3A), CCL21 (Figure 3E), and ICAM-1
(Figure 3F) when compared to both MSC-treated groups (DA-
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FIGURE 2 | MSC pre-treatment induces enhanced creatinine levels
and impairs kidney cortex architecture. Blood creatinine levels were
measured 8–10 days after kidney transplantation and data are presented
as mean ± SEM with 4–6 rats in each group (A); *P < 0.05. Transplanted
kidneys were then harvested, ﬁxed with 2% PFA for 2 h, incubated in sterile
30% sucrose and embedded. Five to eight micron thick sections were
stained with Harris’s hematoxylin followed by Eosin to evaluate tissue
integrity. Representative images are shown for rats injected 4 days prior
to transplant with (B) DA-MSC, (C) LEW-MSC, or (D) PBS. Scale bars
represent 100 μm.
and LEW-MSC). IFNγ, IL-1β, IL-6, and CD25 mRNA expression
was rather comparable between all groups (Figures 3B–D,G).
Analyzing the mRNA expression levels in recipient spleens, we
generally detected low expression levels for nearly all tested mark-
ers, except for CD25 (Figure 4). In addition, both MSC-treated
groups displayed higher CD25 mRNA expression levels relative to
the PBS control group (Figure 4H). Notably, values within the
DA-MSC-injected group were more variable between the single
recipients. Although not signiﬁcant, more animals per group with
higher expression levels were detected for the DA-MSC group and
especially for the markers IL-1β (Figure 4C), ICAM-1 (Figure 4F),
and MHCII (Figure 4G).
IMPACT OF MSC ON CELLULAR INTRAGRAFT INFILTRATION
Kidney grafts were analyzed by immunohistological staining for
their cellular inﬁltration pattern at post-operative days 8–10 by
staining with antibodies to the major subsets of immune cells.
In Figure 5, the summarized data of staining scores for B cells,
T cells, CD68+ macrophages, CD45+ leucocytes, and MHCII+
APC are shown. Signiﬁcant differences between the experimen-
tal groups treated with LEW-MSC compared to DA-MSC-treated
and PBS control animals were detected regarding the scores
for TCR-positive cells (Figure 5A) and B cell marker-positive
cells (Figure 5B). Surprisingly, higher values were detected for
the LEW-MSC-treated group relative to the DA-MSC- and also
the PBS-treated group as illustrated in representative images
(Figures 5F–H). For all the other markers tested; CD68, CD45,
and MHCII, the scores were comparable (Figures 5C–E).
DEPOSITION OF COMPLEMENT FACTOR C4d IN THE KIDNEY CORTEX
To evaluate whether humoral mediated responses might con-
tribute to the poorer graft function of MSC-treated rats, we
performed immunoﬂuorescence staining for C4d deposits. The
staining intensities of the ﬂuorescence signal on microscopic
images of all samples were quantiﬁed by a speciﬁc algorithm of
the ColumbusTM Image Data Storage and Analysis System and
the total area of positive staining (pixels2) was calculated for all
treatment groups (Figure 6A). Representative images of the C4d
staining for all treatment groups are shown (Figures 6B–D) as well
for the quantiﬁcation method (Figure 6E). A control staining per-
formed using a transplanted syngeneic kidney demonstrated the
absence of C4d deposits when rejection was not induced (please
refer to Appendix Figure A2). It is apparent that LEW-MSC-
treated animals express higher levels of C4d in the kidney cortex
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FIGURE 3 | Inflammation within the kidney grafts following MSC
pre-treatment measured by intragraft gene expression analysis.
Quantitative real-time PCR was performed on kidney grafts harvested 8–10
days after transplant. After expression of the target gene was normalized to
the housekeeping gene β-actin, the mean fold increase of the target gene in
the test samples compared to the values in the kidneys of three naïve rats
was calculated using the formula 2−CT for (A)TNFα, (B) IFNγ, (C) IL-1β,
(D) IL-6, (E) CCL21, (F) ICAM-1, and (G) CD25. Data are presented as the
mean ± SEM of the mean fold change from ﬁve to six transplanted rats per
group from PCR analyses performed in duplicate.
FIGURE 4 | Elevated immune cell activation in rat spleens following MSC
pre-treatment measured by gene expression analysis. Quantitative
real-time PCR was performed on spleens harvested 8–10 days after kidney
transplantation. After expression of the target gene was normalized to the
housekeeping gene β-actin, the mean fold increase of the target gene in the
test samples compared to the values in the spleens of three naïve rats was
calculated using the formula 2−CT for (A)TNFα, (B) IFNγ, (C) IL-1β, (D)
IL-6, (E) CCL21, (F) ICAM-1, (G) MHCII, and (H) CD25. Data are presented as
the mean ± SEM of the mean fold change from ﬁve to six transplanted rats
per group from PCR analyses performed in duplicate.
area then DA-MSC-treated rats but without signiﬁcant differences
between both treatment groups and the PBS-injected group.
INDUCTION OF DONOR-SPECIFIC ANTIBODIES BY MSC APPLICATION
Sera of all LEW recipient rats were screened for the presence of
donor (DA)-speciﬁc antibodies at the time point of graft har-
vest using a ﬂow cytometry based assay with isolated thymocytes.
The geometric MFIs were calculated by subtracting the value of a
naïve rat from the value of all kidney transplant recipient rats
and a representative histogram of the ﬂuorescence staining is
shown in Figure 7A. As shown in the summarized data a distinct
and signiﬁcantly higher MFI for donor-speciﬁc IgG antibodies
was measured for the DA-MSC-treated group in comparison to
the LEW-MSC and PBS group (Figure 7B). IgM antibody val-
ues were only marginally enhanced in the DA-MSC-treated group
(Figure 7C).
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FIGURE 5 | Enhanced intragraft accumulation of T and B cells
following MSC pre-treatment measured by immunohistology. Five
to eight micron thick sections of transplanted kidneys were labeled with
speciﬁc monoclonal mouse anti-rat antibodies to (A)TCR, (B) B cell
marker, (C) CD68, (D) CD45, and (E) MHCII overnight at 4◦C. A
biotin-conjugated secondary antibody and streptavidin/HRP were
applied before visualization with the substrate solution and counterstaining
with Harris’s hematoxylin. Staining scores are given as mean ± SEM
for triplicate slides with ﬁve to six rats in each group; *P<0.05. Representative
images of B cell staining are shown for rats injected 4 days prior to
transplant with (F) DA-MSC, (G) LEW-MSC, or (H) PBS. Scale bars
represent 50μm.
Whether the higher levels of IgG donor-speciﬁc antibodies
within the DA-MSC-treated group correlated with higher B cell
activity in the spleen was analyzed by immunohistological staining
of tissue sections with B cell- and MHCII-speciﬁc antibodies
(Figure 8). The staining intensity score for MHCII was signiﬁ-
cantly enhanced in the DA-MSC transplant group compared to
the PBS-treated control (Figure 8A). A trend toward an increase
in MHCII was also observed for the LEW-MSC group. In contrast,
B cell staining scores were nearly equal for all treatment groups
(Figure 8B).
DISCUSSION
In the present study, we investigated the effect of the donor-
type MSC pre-treatment on the modulation of inﬂammation
and rejection responses in an acute rat renal transplantation
model of high MHC disparity with concomitant immuno-
suppression.
In our clinically relevant transplant model, we found that in
contrast to our expectations, the application of either donor- or
recipient-type MSC 4 days before kidney grafting resulted in the
induction of increased signs of inﬂammation and higher levels of
cellular inﬁltration, especially of B cells, at the time point of rejec-
tion. This was combined with C4d deposits within the glomeruli
and the peritubular capillaries. In addition,whendonor-typeMSC
were applied, signiﬁcantly higher donor-speciﬁc IgG-antibody lev-
els were induced, in contrast to the application of recipient-type
MSC. These data lead us to the conclusion that donor-type MSC
administration before kidney transplantation causes enhanced
humoral rejection processes.
Our data in a renal transplant model are in contrast to the
clear beneﬁcial effects of the day-4 MSC application in a rat
model of heterotopic heart transplantation with the same MMF
immunosuppressive regimen (Popp et al., 2009). We neither see a
prolonged graft survival, nor the development of partial tolerance.
www.frontiersin.org July 2012 | Volume 3 | Article 202 | 7
“ﬁmmu-03-00202” — 2012/7/14 — 20:18 — page 8 — #8
Seifert et al. MSC adversely affect kidney transplantation
FIGURE 6 | Amplified C4d deposits in transplanted kidneys following
MSC pre-treatment. Immunoﬂuorescence labeling was performed on
sections prepared from transplanted kidneys using a polyclonal antibody to rat
C4d incubated overnight followed by detection with an Alexa Fluor® 488
donkey anti-rabbit IgG (H + L) secondary antibody. (A) Images obtained by
ﬂuorescence microscopy were evaluated using the ColumbusTM Image Data
Storage and Analysis System to quantify C4d (green ﬂuorescence) labeling.
Data are given as mean ± SEM for total area of positive “spots” in pixels2
from duplicate images from ﬁve to six rats per group; *P < 0.05.
Representative images of C4d labeling are shown for rats injected 4 days
prior to transplant with (B) DA-MSC, (C) LEW-MSC, or (D) PBS. An example
of the spot identiﬁcation using ColumbusTM software is shown (E) with
various colors indicting quantiﬁed spots for the same PBS-injected animal
image. Scale bars represent 50μm.
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FIGURE 7 | Enhanced levels of donor-specific antibodies in serum
following donor-specific MSC pre-treatment. Serum collected from
transplanted rats at the time of harvest was evaluated for the presence of IgG
and IgM donor-speciﬁc antibodies. (A) A representative staining histogram is
shown for a naïve control serum (black solid line) and a positive test serum
(ﬁlled gray curve). Data were collected using a BD FACS Canto II ﬂow
cytometer and the geometric MFI was determined. Background values for a
naïve animal were subtracted from test rat serum values. Data are presented
for (B) IgG and (C) IgM donor-speciﬁc antibodies as the mean ± SEM of the
geometric MFI from ﬁve to six transplanted rats per group; *P < 0.05.
Discrepancies might be caused by differences in the experimen-
tal parameters including the selected rat strain combination,
and the fact that while the heterotopic heart is not required
for survival, our model requires the transplanted kidney to
function.
Renal grafts were rejected between days 8 and 10 regardless
of whether the groups were pre-treated with MSC or a PBS con-
trol. The overall condition of the animals was extremely poor
in the donor-type MSC-treated group, and higher creatinine lev-
els were measured at the time point of rejection. This was also
reﬂected by the observation of histological signs of destruction
which damaged the typical renal cortex architecture of glomeruli
and tubuli and visible interstitial cellular inﬁltration in HE
staining.
Analyzing the degree of cytokine and cellular marker expres-
sion within the grafted kidneys, we found not signiﬁcantly
changed gene expression levels between the MSC-treated and the
PBS-treated control group. However, most animals in both MSC-
treated groups tended toward higher mRNA expression levels for
the pro-inﬂammatory cytokine TNFα and the chemokine CCL21
as well as cellular markers of immune cell activation (e.g. ICAM-1,
CD25). Therefore, the protective effect of MSC by reducing signs
of inﬂammation at early time points after kidney transplantation
we recently described (Hara et al., 2011) seems to be undetectable
in a later phase of the rejection process. In this former in vivo study,
we saw signiﬁcant effects using a higher number of cells which
were injected at multiple time points both before and after trans-
plantation. In addition, the type of immunosuppressive treatment
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FIGURE 8 | Enhanced detection of MHCII-positive cells in rat spleens
following MSC pre-treatment measured by immunohistology. Spleens
were harvested at 8–10 days after kidney transplant and cryosections were
labeled with speciﬁc monoclonal mouse anti-rat antibodies to B cell marker,
MHCII, or with the isotype control antibody overnight at 4◦C. A
biotin-conjugated secondary antibody and streptavidin/horseradish
peroxidase were applied before visualization with the substrate solution
and counterstaining with Harris’s hematoxylin. Triplicate images were
captured from each slide and the intensity of positive brown staining for
(A) MHC II or (B) B cell marker was analyzed in a blinded approach on a
scale of 0–3. Scores are given as mean ± SEM for triplicate slides with ﬁve
to six rats in each group; *P < 0.05.
(Cyclosporine A instead of MMF) might inﬂuence the difference
in MSC effectiveness observed.
Splenic mRNA levels for IL-1β and for ICAM-1 and MHCII
also trended toward an increase in the donor-type MSC-treated
group, indicating signs of sensitization against the donor type cells
and induced immunogenicity. Whether the observed marginally
higher CD25 expression in both MSC-treated groups is related to
expansion of regulatory T cells or activation of conventional T cells
remains unclear.
Our analysis of graft inﬁltrating cell subsets gave rise to inter-
esting and surprising ﬁndings. We observed that B cells were more
abundant within the grafts pre-treated with recipient-type MSC
compared to the PBS control group. T cell and macrophage inﬁl-
tration were not signiﬁcantly different between the PBS and both
MSC groups. Why the donor MSC-treated animals do not display
the same high B cell staining is unclear. One explanation might be
that the process of rejection and organ damage is even more accel-
erated over the same time frame in this group and cells had already
disappeared from the allograft at days 8–10. Hints for stronger
organ damage in the donor MSC-treated group were clearly seen
in the HE histology and additionally resulted in higher blood cre-
atinine levels. Whether the higher B cell inﬁltration within the
kidneys and the higher degree of graft destruction is caused by
enhanced IL-6, as described in rat kidney transplantation models
with low weight grafts (Gong et al., 2009) was examined. However,
we detected neither signiﬁcantly elevated mRNA expression levels
for IL-6 in the grafted kidneys, nor higher levels of circulating IL-6
in the serum of MSC-treated animals at the time point of rejection
(data not shown). Future studies could clarify if MSC cause a rise
in systemic IL-6 levels soon after they are injected which decreases
over time.
It is known that B cells are an important immune cell sub-
set with antigen-presenting capacity in renal graft rejection. B
cell involvement is in general characterized by intragraft B cell
inﬁltration, C4d deposition and circulating donor-speciﬁc anti-
bodies (Barnett et al., 2011). In humans, about 5–7% of the kidney
transplant patients develop acute humoral rejection (Takemoto
et al., 2004). Therefore, we had a closer look into the detection of
complement factor deposits and the circulation of donor-speciﬁc
antibodies. Animals that were treated with recipient-type MSC
have signiﬁcantly higher levels of C4ddeposits andmore inﬁltrated
B and T cells, when compared to the donor-type MSC group.
The analysis of the donor-speciﬁc antibody levels demonstrated
a detectable IgG response in all animals which we attribute to
the transplant of a strongly mismatched kidney. However, IgG
levels were signiﬁcantly higher in the donor MSC-treated group.
These results clearly demonstrate the sensitization in recipients
to the donor-type antigen resulting in a more accelerated rejec-
tion process. Our observations are in agreement with evidence
from other groups demonstrating recognition of MSC by the
adaptive immune system (Crop et al., 2011) or even sensitization
of the recipient (Nauta et al., 2006; Sbano et al., 2008). Another
group has recently published that i.v. injection of allogeneic MSC
provoked the generationof allo-antibodies and that repeated injec-
tions reduce the survival of injected allogeneic MSC (Schu et al.,
2011). However, it still remains unclear how this may interfere
with their potential immunomodulatory effects in pre-clinical or
clinical trials (Grifﬁn et al., 2010; Hoogduijn et al., 2011).
The ﬁrst clinical study in kidney transplantation with autol-
ogous MSC treatment was reported by Perico et al. (2011) as a
safety and feasibility study, but with limited success. Other groups
are preparing to set up clinical trials using autologous or even
allogeneic MSC as described in a recent review (Roemeling-van
Rhijn et al., 2012). Although in solid organ transplantation new
treatment strategies are essential, our results from the pre-clinical
rat kidney transplantation model advise that MSC administra-
tion may not be optimal in all types of solid organ transplants
and also that the speciﬁc treatment regimen might be crucial
for graft success. Contrary data have also been published for the
rat heart transplantation model, with either accelerated rejection
(Inoue et al., 2006) or prolonged graft survival (Popp et al., 2008)
obtained depending on the experimental approach. Therefore, the
time point of injection, number of cells applied and the type of
immunosuppressive treatments used seem tobe important param-
eters inﬂuencing the success of the MSC treatment. A recent study
using autologous MSC as a replacement for induction therapy
in living, related kidney transplants (Tan et al., 2012) demon-
strated reduced acute rejection, faster recovery of renal function
and reduced opportunistic infections. Whereas, another group
observedprolongedgraft survival by aTreg-dependentmechanism
in a mouse model of kidney transplantation where they applied
a pre-treatment of animals with syngeneic MSC (Casiraghi et al.,
2012), indicating that the proper time point for MSC administra-
tion is still up for debate. Nevertheless, based on conﬂicting results
in pre-clinical studies caution must be exerted in order to avoid
adverse effects in future clinical studies.
Though the administration of whole MSC may lead to adverse
effects, it is possible that many of the positive effects published in
earlier studies could be due to paracrine modes of MSC action.
As many researchers do not believe that MSC act to improve
regeneration by differentiating into cells of the target organ to
exert their effects (Tögel et al., 2007; Wise and Ricardo, 2012),
rather that they might work by secreting paracrine factors or
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microvesicles (Bruno et al., 2009; Gatti et al., 2011; Ratajczak,2011;
Tetta et al., 2011), we would suggest that further studies focus on
investigating the positive protective effects of MSC in organ regen-
eration without the risks of injecting whole cells. This approach
would also alleviate concerns related to the possible malignant
outgrowth of MSC injected into a patient subjected to long-term
immunosuppression.
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APPENDIX
FIGUREA1 | FACS histograms of a representative labeling of LEW MSC
(recipient-type) and DA MSC (donor-type) with antibodies against rat
MHC I and MHC II are shown (gray filled curve) in comparison to labeling
with the isotype control antibody (black bold line). Both MSC types
constitutively express MHC I, but not MHC II. Data were collected using
a BD FACS Canto II ﬂow cytometer analyzed using FlowJo software.
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FIGUREA2 | Representative images of kidney cortex tissue of two
animals 3 days after syngeneic kidney transplantation are shown.
Cryostat sections of the kidney tissue were stained with an anti-C4d
antibody (upper row) or with HE (lower row); original magniﬁcation × 20.
Both rats show a normal kidney cortex architecture and lack speciﬁc
C4d signal.
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